Arterial hypertension is an important risk factor for the development of cognitive and psychoemotional disorders

In the recent years timely identification and management of cognitive and psychoemotional disorders in patients with the most common chronic non-communicable diseases has acquired special importance. Arterial hypertension (AH) is the most significant factor for the development and progression of cognitive and psychoemotional disorders. The development of AH in young and middle-aged adults is a particularly unfavourable prognostic fact. A search is currently underway for therapeutic neuroprotective strategies that can effectively prevent or reduce the damaging pathophysiological effects of hypertension on the brain. For over almost 30 years of active clinical use of the original ethylmethylhydroxypyridine succinate (EMHPS) the enormous clinical experience and evidence of therapeutic benefits in patients with various types of vascular and metabolic disorders have been accumulated. The principal pharmacological effects of EMHPS are antioxidant, antihypoxic, and membrane-protective, due to which the drug produces nootropic, anxiolytic, vegetative-stabilizing and other clinical effects. The favourable effect of EMHPS on the blood vessel wall, endothelial function and rheological properties has also been confirmed, which presents an important component of the complex therapy of a modern patient with AH. The international multicenter, randomized, double-blind and placebo-controlled study MEMO and its subanalysis showed that EMHPS is significantly effective in improving cognitive functions, anxiety and asthenia levels and patient’s quality of life during the long-term sequential therapy in patients with concomitant hypertension.